Abiopharma

🔍 Manning Paul B (Executive)

Company: Liquidia Corp (LQDA)

Report Date: 2025-08-28

Detailed Transactions and Holdings:

• Sold 154,337 shares of Common Stock at $27.94 per share (Direct)
  Date: 2025-08-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 947,328.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 188,232 shares of Common Stock at $27.62 per share (Direct)
  Date: 2025-08-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 759,096.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 254,038 shares of Common Stock at $28.67 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 505,058.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 74,230 shares of Common Stock at $29.14 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 430,828.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 816,311.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 435,674.00 | Footnotes: F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 198,413.00 | Footnotes: F8
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 898,335.00 | Footnotes: F9
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | shares_owned_after: 38,755.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: H | shares_owned_after: 3,131,794.00 | Footnotes: F10

Footnotes:

• F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5).
• F2: The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT.
• F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.77 inclusive.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $29.065 inclusive.
• F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.25 inclusive.
• F6: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
• F7: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.
• F8: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.
• F9: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.
• F10: The shares are held by Reporting Person jointly with his spouse.